PubMed:17980029 / 1631-1953 JSONTXT

Annnotations TAB JSON ListView MergeView

    sentences

    {"project":"sentences","denotations":[{"id":"TextSentencer_T15","span":{"begin":0,"end":322},"obj":"Sentence"},{"id":"T15","span":{"begin":0,"end":322},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The enhancement was associated with decreasing levels of tissue inhibitor of matrix metalloproteinase (TIMP)-2 and increasing levels of the urokinase-type plasminogen activator receptor (uPAR), Ets-1 (E26 transformation-specific-1), matrix metalloproteinase (MMP)-9 and RhoC (ras homolog gene family, member C) expression."}

    UBERON-AE

    {"project":"UBERON-AE","denotations":[{"id":"PD-UBERON-AE-B_T8","span":{"begin":57,"end":63},"obj":"http://purl.obolibrary.org/obo/UBERON_0000479"}],"text":"The enhancement was associated with decreasing levels of tissue inhibitor of matrix metalloproteinase (TIMP)-2 and increasing levels of the urokinase-type plasminogen activator receptor (uPAR), Ets-1 (E26 transformation-specific-1), matrix metalloproteinase (MMP)-9 and RhoC (ras homolog gene family, member C) expression."}

    performance-test

    {"project":"performance-test","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":57,"end":63},"obj":"http://purl.obolibrary.org/obo/UBERON_0000479"}],"text":"The enhancement was associated with decreasing levels of tissue inhibitor of matrix metalloproteinase (TIMP)-2 and increasing levels of the urokinase-type plasminogen activator receptor (uPAR), Ets-1 (E26 transformation-specific-1), matrix metalloproteinase (MMP)-9 and RhoC (ras homolog gene family, member C) expression."}